WINDSOR, ON / ACCESSWIRE / June 16, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the seldom huge potential of the OTC market when used as a proper stepping-stone to a national stock exchange.
Very seldom do you see long-term success in the sometimes scary OTC market. One might gauge long-term success as assembling a world class management team, raising some capital on not-so-good terms, and bringing a business plan to the point where it’s considered a valuable asset. Down this road, there are many more things that can go wrong than can go right. The proverbial pot of gold at the end of the rainbow would be the infamous “up-listing” to the NASDAQ or the NYSE-by way of achieving the aforementioned goals, but also quantifiable goals like share price and book value increases. It’s not an easy task.
The biggest success story in this category in recent history (there are a few more we may detail in later articles) is without a doubt Advaxis Inc. (NASDAQ: ADXS). It helps that ADXS in in the white-hot immunotherapy space, but in all fairness, everything under the healthcare umbrella is outperforming. Time to look for another potential “Advaxis”; all you have to do is find strong companies in earlier stages of their research (and have a bit of luck). Investors who bought Advaxis back when it was on the OTC exchange 2 years ago have been treated to gains in the 500% – 1,000% range. ADXS is having great success with their main drug in clinical trials indicated to treat cervical cancer.
Propanc Health Group (OTC: PPCH) is a Company we’ve been mentioning since it was $0.0038; it’s now a staggering 2,700% higher in the realm of $0.10-investors who invested $10,000 may have over a quarter million dollars now. The Company just had research coverage (http://www.seethruequity.com/#!ppch/c5jp) giving them a $1.52 price target which is 1,400% higher than the current price. This may be aggressive, but they are working on a treatment for aggressive cancers, such as pancreatic, which currently have limited treatment options, as well as cancers with large unmet medical need, such as colorectal cancer, where a high mortality rate still exists. Technicians looking at the stock chart may argue that the supply of sellers in the $0.10 range is wearing thin, and could pose a potential break-out opportunity for traders.
Looking even further in the rear-view mirror we look for promising companies / business plans, with stand-out management teams who can raise capital for their ideas-in this instance we look for stocks which haven’t had a big run yet, as the initial breakout is where the lion’s share of profits are usually made. Falling into this category The Wealthy Biotech Trader is alerting Investors of a catalyst prone stock PositiveID Corp. (OTC: PSID). Provided the Company keeps making progress on their new Firefly Dx unit, we feel this could be a big winner. Readers should take a minute to read this brief overview of PSID and its star product, the Firefly: http://goo.gl/g4K3WT. There are several potential catalysts that could move this stock upwards, and we will keep readers apprised via Twitter and Facebook-we also release research notes via press release, so put it on your watch list of trades to make. The shares are trading at a paltry $0.016 giving the company a market value of only $4.7 Million.
Another noteworthy company in the healthcare space, more specifically in the biotech space, is Taplmmune (OTC: TPIV). TPIV is also in the super-hot space of immunotherapy like Advaxis (NASDAQ: ADXS). Being in the immuno-oncology space may be one of the main reasons for the stock’s recent aggressive move upwards, but could also be attributed to some of the positive news the company has updated investors on upcoming phase II trials for their lead product(s) TPIV100/200. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing).
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports / updates / news through Twitter and Facebook as well as newswire.
GET BREAKING NEWS FROM US:
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader’s parent company has been and will continue to be compensated $25,000 per month by PositiveID. The Wealthy Biotech Trader’s controlling parent company has also been compensated $62,500 by PositiveID in the form of a convertible note and readers should understand that they will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader’s parent company has been and will be compensated roughly $5,000 per month by Propanc Heath Group. The Wealthy Biotech Trader’s controlling parent company has also been compensated $60,000 by Propanc Heath Group in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
SOURCE: The Wealthy Biotech Trader